Search for: "AT&T Services Inc. " Results 9581 - 9600 of 17,734
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 Nov 2013, 4:00 am by Administrator
Agence de ventes Bill Sayer Inc. 2004 CanLII 26433 (QCCA) [5] L'appelante ne conteste que la durée du délai-congé fixé par le premier juge et le montant des indemnités relatives au congédiement de son employé: la première, de 283 600 $, tient lieu d'un préavis à la société de l'intimé, la seconde, pour dommages moraux, s'élève à 30 000 $ et est payable à… [read post]
11 Nov 2013, 9:09 pm by Eugene Volokh
See Dayton Area Visually Impaired Persons, Inc. v. [read post]
11 Nov 2013, 10:59 am by Parker Higgins
An online service's users deserve to be protected from fishing expeditions like this one." [read post]
8 Nov 2013, 9:48 am by Rebecca Tushnet
Napster as service: litigation empirically stifled innovation, caused venture capital to dry up. [read post]
5 Nov 2013, 5:04 pm
With regard to this last requirement, the educational program must include: Airing 160 public service announcements (80 on the station's primary channel and 80 on its multicast channel). [read post]
4 Nov 2013, 9:56 pm by Jon Gelman
A year after J&J had received the results of a second study confirming the increased safety risk for elderly patients taking Risperdal, but had not published the data, one physician who worked on the study cautioned Janssen that “[a]t this point, so long after [the study] has been completed … we must be concerned that this gives the strong appearance that Janssen is purposely withholding the findings. [read post]
4 Nov 2013, 9:46 am by Jane Chong
If that ends up being the case, it won’t be for lack of theorizing. [read post]
4 Nov 2013, 9:08 am
  In Planned Parenthood of Greater Texas Surgical Health Services v. [read post]
4 Nov 2013, 3:04 am by Ben Vernia
On November 4, the Department of Justice announced that Johnson & Johnson and its subsidiaries, Janssen Pharmaceuticals, Inc., and Scios, Inc., had agreed to pay $2.2 billion to resolve claims originally brought by whistleblowers that the company promoted its drugs Risperdal, Invega, and Natrecor for unapproved (off-label) uses. [read post]